Overview
Pazopanib Maintenance for SCLC
Status:
Completed
Completed
Trial end date:
2017-12-01
2017-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To evaluate the efficacy of pazopanib maintenance after 1st line CTx for SCLC.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Samsung Medical Center
Criteria
Inclusion Criteria:- histologically confirmed SCLC
- no disease progression after 4 cycles of etoposide/platinum 1st-line therapy
- history of 4 cycles of etoposide/platinum 1st-line therapy
- between 21 days and 42 days since C4D1 of etoposide/platinum
- no symptomatic brain meta
Exclusion Criteria:
- poor hepatic, renal function